Asset profile
HRS-9821
Small molecule
Evidence outlook · lead readout
NCT05622864 · Chronic Obstructive Pulmonary Disease
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT05622864: The study is described as randomized and blinded, but the available record does not clearly show a placebo or comparator arm alongside the two active-dose groups, so how controlled the comparison actually is cannot be fully confirmed. Its primary measure is also safety monitoring rather than the lung-function endpoints, and no results have been posted yet.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
October 2026 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.